Access the University of Edinburgh’s research expertise, technologies and advanced facilities to make discoveries and translational developments in human therapeutics.
Collaborate with us to deliver solutions for the future of health and care: clinical trials, data, animal models, cell-based testing, and cell-free testing.
Senior Consultancy Manager, College of Medicine and Veterinary Medicine.
Business Development Executive, College of Medicine and Veterinary Medicine.
Developing safe and effective gene therapies by harnessing the power of engineering biology. Advancing healthcare by developing the next generation of controllable gene therapies: right location, level and time.
Edinburgh Genome Foundry (EGF) specialises in the modular assembly of DNA constructs using a highly automated robotic platform. The research facility builds genetic constructs for customers to equip cells or whole organisms with new or improved functionalities. EGF works on projects as diverse as programming stem cells for use in personalised medicine, vaccine development, gene therapy (including viral vectors) and living biosensors. Services include DNA Design and Project Planning, DNA Assembly, Cell Phenotyping, Laboratory Equipment and Protocols and DNA Design and Lab Automation Software.
The Healthcare Technology Accelerator Facility supports drug development with small batch manufacturing services at all stages of the drug development process.
The Large Animal Research and Imaging Facility (LARIF) allows users to benefit from a wide range of expertise in farm animal production, health and welfare - including infectious diseases and zoonoses, vaccines, genetics and genome editing, imaging, radiology, medicine, surgery and critical care. Facilities include imaging technology, an isolation suite, surgical facilities, genetic modification and a critical care unit.
Laboratories, offices and expert teams to support the development of robust cell therapy manufacturing processes and accelerated routes to the clinic.
EuroGCT (formerly EuroStemCell) provides independent, expert-reviewed information and road-tested educational resources on cell and gene therapies and their impact on society. EuroGCT also works with people affected by conditions, educators, regulators, media, healthcare professionals and policymakers to foster engagement and develop material that meets their needs.
The Healthcare Technology Accelerator Facility supports drug development with small batch manufacturing services at all stages of the drug development process.
The MRC/BHF CoRE in Advanced Cardiac Therapies (REACT) unites academic, healthcare, industry and public partners to develop innovative DNA and RNA-based therapies to regenerate injured hearts and reverse established damage.
